![]() Drimmer brings a wealth of experience in legal oversight and executive leadership in corporate governance, contracting and operations. ![]() in sociology from San Jose State University and is a member of CSHRP, Community for Strategic HR Partnerships.Īs Tenaya’s General Counsel, Ms. Auch held roles at IXIA and JumpstartMD where she built out HR operations, total rewards, performance management and leadership effectiveness tools. Most notably, she led the human resources integration of multiple company acquisitions, driving a united team and one company culture. Auch collaborated to drive organizational capabilities and scalable programs during a time of rapid growth and commercialization. Auch brings more than 15 years of hands-on senior leadership experience from multiple industries including pharmaceutical, healthcare and technology.īefore joining Tenaya, she was the Head of Human Resources, North America for Santen, Inc., a global pharmaceutical company focused on ophthalmology. Her focus is on delivering people strategies that engage, develop and grow our team members. Auch is the Senior Vice President of People and Culture and is responsible for leading all HR programs that drive our “One Tenaya” team culture. Senior Vice President, People and Culture He completed his post-doctoral training at Cornell University and received his doctoral degree in chemical engineering from Colorado State University. Kim had roles of increasing leadership at several technical organizations including Aeras TB Foundation and Walter Reed Army Medical Center. Kim was responsible for the process development, manufacturing science and related regulatory filings for Dendreon’s commercial product PROVENGE™. Kim also ran his own biopharma consulting firm, which he started after serving as Director of Process Development at Avalanche Biotechnology (now Adverum). Prior to that, he was the Head of Gene Therapy Process Development and the Global CMC Lead of Gene Therapy at Shire. Kim was Senior Vice President, Head of Technical Operations at Agilis Biotherapeutics, where he had accountability for manufacturing of gene therapy drug products and establishing reliable clinical and commercial supply chains. During his tenure, he has led the company’s effort to internalize process development, analytical development and quality control capabilities, and overseen the establishment of Tenaya’s cGMP manufacturing facility. Prior to joining Tenaya, Dr. Kim joined Tenaya in 2018 to serve as Senior Vice President of Technical Operations. Patterson is also a Certified Public Accountant (inactive status).ĭr. in business administration and accounting from Chapman University and an executive MBA from St. Patterson serves on the board of directors of Nkarta, Inc., a publicly-held clinical-stage biopharmaceutical company. Earlier in her career she worked in the audit practice of accounting firm KPMG. She also held senior finance positions at Exelixis, Novartis and Chiron. Patterson was Chief Financial Officer at both Diadexus and Transcept. Patterson joined Tenaya from Adverum Biotechnologies where she served as President and Chief Financial Officer, and previously held the positions of CEO and Director. Patterson joined Tenaya in June 2021 as Chief Financial and Business Officer, leading corporate finance, investor relations, corporate communications, strategy and business development, as well as other operational functions. He was appointed to the Board of Directors for The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, in 2022. Ali received his MBA from Harvard Business School and his B.S. ![]() He started his career at General Electric, including technical roles at GE Healthcare and business assignments at GE Corporate. Ali also had roles of increasing global commercial leadership at Genzyme Corporation, where he helped launch multiple first-in-class enzyme replacement therapies for rare diseases. Prior to that, he was a vice president at bluebird bio, where he had accountability for new product planning, program management, patient advocacy and external affairs. Ali was most recently chief business officer at REGENXBIO, where he had accountability for corporate development, commercial planning, portfolio strategy, alliance management and corporate communications.
0 Comments
Leave a Reply. |